Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies.


Commonly reported comparisons of differences in disease progression according to disease staging at therapy initiation may be subject to bias if they do not account for the time it took the deferred group to reach the latter stage (that is, leadtime) and for previous events in those who initiate therapy at late stage (that is, unseen fast progressors). To… (More)

5 Figures and Tables


  • Presentations referencing similar topics